Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2019-2023 | 39% CAGR Projection Over the Next Five Years | Technavio

Technavio has announced its latest market research report titled global BCL-2 inhibitors market 2019-2023. (Graphic: Business Wire)

LONDON--()--The global BCL-2 (B-Cell lymphoma 2) inhibitors market is expected to post a CAGR of close to 39% during the period 2019-2023, according to the latest market research report by Technavio.

A key factor driving the growth of the global BCL-2 (B-Cell lymphoma 2) inhibitors market size is the growing awareness about hematological malignancies. The symptoms of hematological malignancies are often mild or not apparent, which results in a delay in the diagnosis and treatment of the indications. Thus, various vendors and organizations are conducting awareness programs to educate patients about the possible symptoms and severity of the indications. These programs are aimed at helping patients in the early detection of the indication, which renders the treatment using effective therapeutics. This is expected to propel the adoption of B-Cell lymphoma 2 during the forecast period.

As per Technavio, the development of novel formulations will have a positive impact on the market and contribute to its growth significantly over the forecast period. This global BCL-2 (B-Cell lymphoma 2) inhibitors market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.

Global BCL-2 (B-Cell lymphoma 2) Inhibitors Market: Development of Novel Formulations

A rise in the number of CLL/SSL and AML has increased the demand for novel formulations. The available BCL-2 inhibitors are associated with various side effects and are comparatively less effective than other biologics in the market. This is increasing the requirement of novel therapies with fewer adverse effects. Thus, various vendors are striving to develop new-age BCL inhibitors with higher efficacy and minimal side effects. The advances in research to develop novel formulations will fuel the growth of the B-Cell lymphoma 2 inhibitors market during the forecast period.

“Apart from the development of novel formulations, other factors such as the strategic partnerships and collaborations, and the increase in patient assistance programs will have a significant impact on the growth of the BCL-2 (B-Cell lymphoma 2) inhibitors market value during the forecast period,” says a senior analyst at Technavio.

Global BCL-2 (B-Cell lymphoma 2) inhibitors Market: Segmentation Analysis

This market research report segments the global BCL-2 (B-Cell lymphoma 2) inhibitors market worth by product (combination therapy, and monotherapy), and geographic regions (North America, Europe, Asia, and ROW).

The North America region led the BCL-2 (B-Cell lymphoma 2) inhibitors market in 2018, followed by Europe, Asia, and ROW respectively. The dominance of the BCL-2 inhibitors market share in North America can be attributed to the high prevalence of AML and CLL/SLL in the US, and the recent approval of venetoclax combinations.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Release Summary

The global BCL-2 (B-Cell lymphoma 2) inhibitors market is expected to post a CAGR of close to 39% during 2019-2023, according to Technavio.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200